通过不同类型的减肥干预措施,DNA甲基化与血糖结果有差异关联:一项全表观基因组关联研究
Xiaoxiao Wen1, Helena Palma-Gudiel1, Guanhong Miao1
1Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, 2004 Mowry Road, CTRB 4230, Gainesville, FL, 32610, USA.
Clinical epigenetics
|July 1, 2023
概括
基线DNA甲基化 (DNAm) 可以预测不同的减肥干预措施如何改善血糖控制. 这项研究发现,与医疗干预相比,减肥手术后的更好的结果相关的特定DNAm模式.
科学领域:
- 表观遗传学和代谢疾病
- 基因组学和个性化医学
背景情况:
- 减肥干预措施,特别是减肥手术,通过诸如DNA甲基化 (DNAm) 变化等机制改善代谢健康.
- 之前的研究集中在干预后的DNAm变化;这项研究调查了干预前DNAm在预测血糖结果中的作用.
研究的目的:
- 为了确定基线DNAm是否与各种减肥干预后的血糖结果有差异性相关.
- 探索DNAm作为一种潜在的生物标志物,用于预测个人对干预措施的反应,例如密集医疗干预 (IMI),可调节的胃带 (BAND) 和Roux-en-Y胃旁路 (RYGB).
主要方法:
- 分析了75名严重肥胖的成年人接受IMI,BAND或RYGB.
- 在干预后1年测量了快速血葡萄糖 (FPG) 和糖化血红蛋白 (HbA1c) 的变化.
- 利用Illumina 450K阵列进行基线DNAm量化,并进行全表观基因组关联研究,包括干预类型和DNAm之间的相互作用术语,调整体重减轻和临床因素.
主要成果:
- 在基线确定了3216和117个CpG探针,在将RYGB与IMI进行比较时,与FPG和HbA1c的变化分别存在差异.
- 在RYGB与IMI比较中,发现79个CpG与FPG和HbA1c的变化显著相关,其中富含的基因参与了发热和恒温.
- 在将RYGB与BAND进行比较时,发现了6个CpG与HbA1c变化有差异相关.
结论:
- 基线DNAm水平与不同减肥干预措施的血糖结果独立相关,无论减肥.
- 这些发现表明,基线DNAm可能作为不同减肥策略对差异性血糖反应的预测生物标志物.
- 强调了个性化方法在管理与肥胖相关的代谢并发症方面的潜力.
相关概念视频
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
238
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
238
Genomic Imprinting and Inheritance
34.7K
Diploid organisms inherit genetic material through chromosomes from both parents. Copies of the same gene are known as alleles. In most cases, both alleles are simultaneously expressed and allow various cellular processes to function optimally. If one of the alleles is missing or mutated, the expression of the other allele can compensate; however, this is not true for all genes.
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
34.7K
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K


